1 Stock to Buy This Week and 1 Stock to Dump

NASDAQ: VRTX | Vertex Pharmaceuticals Inc. News, Ratings, and Charts

VRTX – Investors’ sentiment is significantly mixed at the moment, with market volatility at its peak. It could be wise to buy quality stock Vertex Pharmaceuticals (VRTX), which possesses robust financials. However, fundamentally weak stock NeoGenomics (NEO) is best avoided now. Read on….

Amid sky-high inflation and consecutive rate hikes, the U.S. GDP slumped 0.9% in the second quarter, following a 1.6% contraction in the first quarter. However, many, including President Biden, have refused to tag this as a recession as of now. He said, “If you look at our job market, consumer spending, business investment, we see signs of economic progress in the second quarter, as well.”

On the other hand, July was the best month for Wall Street investors since November 2020, with the S&P 500 gaining 9.1% in the month. The market was buoyed by large companies posting better-than-expected financial results.

Nonetheless, market volatility is palpable and seems to concern the broader markets. The CBOE Volatility Index has gained 32.9% year-to-date.

Given the backdrop, it could be wise to scoop up the quality stock Vertex Pharmaceuticals Incorporated (VRTX - Get Rating), which possesses robust financials. However, fundamentally weak stock NeoGenomics, Inc. (NEO - Get Rating) might be best avoided now.

Stock to Buy:

Vertex Pharmaceuticals Incorporated (VRTX - Get Rating)

Biotechnology company, VRTX, develops and commercializes therapies for treating cystic fibrosis. VRTX also works with investigational small molecules, cell, and genetic therapies, for other serious diseases like sickle cell disease, beta-thalassemia, type 1 diabetes, and others.

On July 11, 2022, VRTX entered into a definitive agreement to acquire ViaCyte, a privately held biotechnology company engaged in delivering novel stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes, for $320 million in cash. This could be a major boost for type 1 diabetes treatment worldwide.

Moreover, VRTX and Verve Therapeutics, Inc. (VERV) announced an exclusive, four-year global research collaboration to develop an in vivo gene editing program for single undisclosed liver disease. VRTX is expected to be responsible for subsequent development, manufacturing, and commercialization of any program stemming from VERV’s research.

For the first quarter ended March 31, 2022, VRTX’s net product revenues increased 21.7% year-over-year to $2.10 billion. Its non-GAAP net income came in at $907 million, up 16.1% year-over-year, while its non-GAAP EPS came in at $3.52, up 18.1% year-over-year. Also, its non-GAAP operating income came in at $1.17 billion, up 16.5% year-over-year.

Analysts expect VRTX’s revenue to be $8.58 billion in 2022, representing a 13.2% year-over-year increase. The company’s EPS is expected to grow 9% year-over-year to $14.19 in 2022. In addition, it has surpassed the consensus EPS estimates in each of the trailing four quarters. Over the past year, the stock has gained 39.9% to close the last trading session at $280.41.

VRTX’s strong fundamentals are reflected in its POWR Ratings. The stock has an overall A rating, equating to a Strong Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.

VRTX has an A grade for Quality and a B grade for Growth and Value. It is ranked first among 402 stocks in the Biotech industry. Click here for the additional POWR Ratings for Momentum, Stability, and Sentiment for VRTX.

Stock to Avoid:

NeoGenomics, Inc. (NEO - Get Rating)

NEO operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. The company provides one of the world’s most comprehensive oncology-focused testing menus. It operates through Clinical Services and Pharma Services segments.

NEO’s total net revenue increased marginally year-over-year to $117.17 million for the first quarter ended March 31, 2022. However, its pharma services revenue came in at $18.38 million, down 3.5% year-over-year. Furthermore, its net loss increased 123.4% year-over-year to $49.41 million, while its loss per share increased 110.5% year-over-year to $0.40.

NEO’s EPS is estimated to fall 192.6% year-over-year to a negative $0.79 in 2022. Its EPS is expected to remain negative in 2023. The stock has lost 77.9% over the past year to close the last trading session at $10.12.

NEO’s POWR Ratings reflect its poor prospects. The stock has an overall F rating, equating to a Strong Sell. It has an F grade for Growth and a D for Value and Momentum.

Click here to access the additional POWR Ratings for NEO (Stability, Sentiment, and Quality). Also, NEO is ranked #51 out of 54 stocks in the D-rated Medical – Diagnostics/Research industry.

Want More Great Investing Ideas?

3 Stocks to DOUBLE This Year


VRTX shares were trading at $277.39 per share on Monday morning, down $3.02 (-1.08%). Year-to-date, VRTX has gained 26.32%, versus a -12.35% rise in the benchmark S&P 500 index during the same period.


About the Author: Riddhima Chakraborty


Riddhima is a financial journalist with a passion for analyzing financial instruments. With a master's degree in economics, she helps investors make informed investment decisions through her insightful commentaries. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
VRTXGet RatingGet RatingGet Rating
NEOGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Why is Stock Market Outlook So Uncertain?

The S&P 500 (SPY) has quickly pushed back from the highs and once again on the verge of a break below the 100 day moving average. Why is this happening? And what comes next? 40 year investment veteran Steve Reitmeister shares his view and top stocks in the commentary that follows...

3 Under-the-Radar Tech Stocks Quietly Powering the Digital Revolution

The technology industry's future seems promising, owing to increasing investments and rising worldwide demand for better products. Hence, investing in fundamentally stable tech stocks, Motorola (MSI), Power Integrations (POWI), and CI&T (CINT) could be the move for investors looking to capitalize on the sector's growth. Read on…

3 AI-Powered Drug Discovery Stocks Revolutionizing Medicine

The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI), propelling the industry’s growth. Amid this backdrop, quality medical stocks Pfizer (PFE), AstraZeneca (AZN), and Novartis (NVS), which are transforming medicine with AI-powered drug discovery, could be ideal portfolio additions. Continue reading...

3 Metaverse Stocks Building the Virtual Economy

The metaverse isn’t just a futuristic fantasy; it’s shaping up to be the next big digital economy. As digital spaces evolve into thriving marketplaces, companies like Apple (AAPL), NVIDIA Corp. (NVDA), and Meta Platforms (META) are building the foundation for this new era. Thus, investing in them could be rewarding. Read more…

Trump or the Fed More Important to Stock Investors?

The S&P 500 (SPY) is flirting with new highs once again. But it is not very clear what is driving these stock price gains. That is why Steve Reitmeister shares his latest views including a market outlook, trading plan and top picks to stay on the right side of the action.

Read More Stories

More Vertex Pharmaceuticals Inc. (VRTX) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All VRTX News